Impact ledger

United Therapeutics Corporation (UTHR): the developments shaping its investment case

Follow the evidence affecting United Therapeutics Corporation. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research United Therapeutics Corporation · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-14 · 9 reports

Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs

Channel: Indirect competitive pressure and legal expense. While UTHR's treprostinil products are established, Yutrepia's growth could erode market share if litigation fails. Legal costs are also a factor.

mixed· 1-3m

2026-09-12 · 5 reports

Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs

Channel: Intellectual property defense and competitive landscape

mixed· 3-12m

2026-09-03

Liquidia Corp Receives FDA Fast Track Designation for YUTREPIA

Channel: Potential future competition in pulmonary hypertension and related indications.

watch· 1-5y

Event impact log

15 events mapped to UTHR since 2026-09-03. Evidence through 2026-09-14.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-14	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs	Indirect competitive pressure and legal expense. While UTHR's treprostinil products are established, Yutrepia's growth could erode market share if litigation fails. Legal costs are also a factor.	mixed	1-3m	0.60
2026-09-14	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues	Direct competition, patent litigation outcome, market share defense	mixed	3-12m	0.70
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit	Direct impact on competitive landscape for PAH treatments and legal expenses. Litigation outcome will determine market share protection.	mixed	3-12m	0.60
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit	Direct competitive pressure vs. intellectual property defense	mixed	3-12m	0.60
2026-09-13	Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle	Direct impact on revenue from competing treprostinil products (Tyvaso), legal expenses, and investor sentiment regarding market dominance.	mixed	3-12m	0.70
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle Persists	Competitive pressure from Yutrepia's growing adoption, offset by potential legal victories.	mixed	1-3m	0.70
2026-09-12	Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs	Intellectual property defense and competitive landscape	mixed	3-12m	0.60
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on Stock	Potential for competitive pressure on existing pulmonary hypertension products (e.g., Tyvaso) if Liquidia's Yutrepia gains full market access. Legal expenses related to patent defense.	mixed	3-12m	0.50
2026-09-12	Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigation	Competitive pressure and legal defense costs. Outcome of litigation will directly affect market share and profitability of their competing product.	mixed	1-3m	0.60
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Continues	Indirect competitive pressure and legal costs related to patent defense.	mixed	1-3m	0.60
2026-09-12	Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms	Competitive pressure from Yutrepia and outcome of patent litigation. Litigation success could protect market share, while failure could lead to increased competition.	mixed	1-3m	0.60
2026-09-12	Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers	Indirect competitive pressure and legal defense costs.	mixed	3-12m	0.50
2026-09-12	Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation looms	Indirect competitive pressure and direct legal/litigation costs.	mixed	3-12m	0.60
2026-09-12	Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fight	Direct impact on competitive landscape for its pulmonary hypertension franchise and potential legal expenses/settlement costs.	mixed	3-12m	0.70
2026-09-03	Liquidia Corp Receives FDA Fast Track Designation for YUTREPIA	Potential future competition in pulmonary hypertension and related indications.	watch	1-5y	0.30

Continue this research

Build your United Therapeutics Corporation investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.